Wednesday, November 25, 2009, 12:13am EST - Canadian Markets open in 9 hours and 17 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Dendreon Corp. (DNDN)

 On Nov 24: 27.20 USD  Down 0.34 (1.23%)  
MORE ON DNDN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Dendreon Corporation (NGM:DNDN) Delayed quote dataEdit
After Hours: 27.20 0.00 (0.00%) as of 7:11pm EST on 11/24/09
Last Trade: 27.20 USD
Trade Time: Nov 24
Change: Down 0.34 (1.23%)
Prev Close: 27.54
Open: 27.56
Bid: 27.05 x 400
Ask: 27.34 x 300
1y Target Est: 34.13
Day's Range: 27.08 - 27.66
52wk Range: 2.55 - 30.42
Volume: 1,476,660
Avg Vol (3m): 3,030,950
Market Cap: 3.15B
P/E (ttm): N/A
EPS (ttm): -1.92
Div & Yield: N/A (N/A%)
Dendreon Corp. (DNDN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add DNDN to Portfolio   Download Data

HEADLINES
• Cel-Sci's History of Disappearing Drugs: BioBuzz
at TheStreet.com (Tue 9:20am)
• BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz
at TheStreet.com (Tue 6:45am)
• Dendreon says FDA will disclose Provenge’s fate by May 1
at bizjournals.com (Fri, Nov 20)
• May Day For Dendreon
at CNBC (Fri, Nov 20)
• Dendreon's Provenge gets FDA review date
AP (Fri, Nov 20)
• Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Fri, Nov 20)
• UPDATE - FDA says Dendreon's drug application is complete
at Reuters (Fri, Nov 20)
• Dendreon Receives FDA Acknowledgement of Complete Response
PRNewswire (Fri, Nov 20)
• Biotech Stock Mailbag: FDA Playbook
at TheStreet.com (Fri, Nov 20)
• This Is Why You're Not Making Money in the Market
at Motley Fool (Tue, Nov 17)
• [$$] Mixed Start
at RealMoney by TheStreet.com (Tue, Nov 17)
More Headlines for DNDN...
ANALYST
EPS Est (next year) (Dec-09) : -1.80
EPS Est (in 2 years) (Dec-10) : -0.64
Avg Rec (current)*: 1.6
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices